Short- vs. long-circulating magnetoliposomes as bone marrow-seeking MR contrast agents

Journal of Magnetic Resonance Imaging

Volumn 9, Issue 2, 1999, Pages 329-335

  Bulte, Jeff W M ^a   De Cuyper, Marcel ^b   Despres, Daryl ^a   Frank, Joseph A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bone marrow; Liposome; MR imaging; Superparamagnetic iron oxide

Indexed keywords

LIPOSOME; MACROGOL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; BONE MARROW; CONTRAST MEDIA; FEMALE; LIPOSOMES; MAGNETIC RESONANCE IMAGING; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0033007218     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199902)9:2<329::AID-JMRI27>3.0.CO;2-Z     Document Type: Article

References (46)

1. Steiner RM, Mitchell DG, Rao VM, et al. Magnetic resonance imaging of bone marrow: diagnostic value in diffuse hematologic disorders. Magn Reson Q 1990;6:17-34.
2. Steiner RM, Mitchell DG, Rao VM, Schweitzer ME. Magnetic resonance imaging of diffuse bone marrow disease. Radiol Clin North Am 1993;31:383-409.
3. Datz FL, Taylor A Jr. The clinical use of radionuclide bone marrow imaging. Semin Nucl Med 1985;15:239-259.
4. Senéterre E, Weissleder R, Jaramillo D, et al. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging. Radiology 1991;179:529-533.
5. Bush CH, Mladinich CRJ, Montgomery WJ. Evaluation of an ultrasmall superparamagnetic iron oxide in MRI in a bone tumor model in rabbits. J Magn Reson Imaging 1997;7:579-584.
6. Daldrup HE, Link TM, Blasius S, Wiedermann D. Rummeny EJ. Bone marrow imaging with AMI 227. In: Proceedings of the 6th Annual Scientific Meeting of the International Society for Magnetic Resonance in Medicine, Sydney, Australia, 1998. p 632.
7. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268:235-237.
8. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066, 29-36.
9. De Cuyper M, Joniau M. Magnetoliposomes. Formation and structural characterization. Eur Biophys J 1988;15:311-319.
10. De Cuyper M. Applications of magnetoproteoliposomes in bioreactors operating in high-gradient magnetic fields. In: Barenholz Y, Lasic DD, editorss. Handbook of nonmedical applications of liposomes. Vol. 3. Boca Raton: CRC Press; 1996. p 325-342.
11. Stookey LL. Ferrozine - a new spectrophotometric reagent for iron. Anal Chem 1970;42:779-781.
12. Bulte JWM, Douglas T, Mann S, Vymazal J, Laughlin PG, Frank JA. Initial assessment of magnetoferritin biokinetics and proton relaxation enhancement in rats. Acad Radiol 1995;2:871-878.
13. Hertzberg C, Orlic D. An electron microscopic study of erythrophagocytosis in the fetal and neonatal rabbit. J Reticuloendothel Soc 1980;28:15-26.
14. Chonn A, Cullis PR, Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 1995;6:698-708.
15. Allen TM. Liposomal drug delivery. Curr Opin Coll Interface Sci 1996;1:645-651.
16. Lasic DD, Papahadjopoulos D. Liposomes revisited. Science 1995; 267:1275-1276.
17. Feigner PL, Tsai YJ, Sukhu L, et al. Improved cationic lipid formulations for in vivo gene therapy. Ann NY Acad Sci 1995;772: 126-139.
18. Harris JD, Lemoine NR. Strategies for targeted gene therapy. Trends Genet 1996;12:400-405.
19. Lee RJ, Huang L. Lipidic vector systems for gene transfer. Crit Rev Ther Drug Carrier Syst 1997;14:173-206.
20. Boerman OC, Storm G, Oyen WJG. Sterically stabilized liposomes labeled with indium-111 to image focal infection. J Nucl Med 1995;36:1639-1644.
21. Phillips WT, Goins B. Targeted delivery of imaging agents by liposomes. In: Torchilin VP, editor. Handbook of targeted delivery of imaging agents. Boca Raton, CRC Press; 1995. p 149-173.
22. Sachse A, Leike JU, Schneider T, et al. Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide-carrying liposomes. Invest Radiol 1997;32: 44-50.
23. Magin RL, Wright SM, Niesman MR, Chan HC, Swartz HM. Liposome delivery of NMR contrast agents for improved tissue imaging. Magn Reson Med 1986;3:440-447.
24. Kabalka G, Buonocore E, Hubner K, Moss T, Norley N, Huang L. Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. Radiology 1987;163:255-258.
25. Unger EC, Shen D-K, Fritz TA. Status of liposomes as MR contrast agents. J Magn Reson Imaging 1993;3:195-198.
26. Trubetskoy VS, Cannillo JA, Milshtein A, Wolf GL, Torchilin VP. Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. Magn Reson Imaging 1995;13:31-37
27. Storrs RW, Tropper FD, Li HY, et al. Paramagnetic polymerized liposomes as new recirculating MR contrast agents. J Magn Reson Imaging 1995;5:719-724.
28. 3-targeted magnetic resonance imaging. Nature Med 1998;4:623-626.
29. Patrizio G, Elizondo G, Fretz C, Eley CGS, Stark DD, Ferrucci JT. Cancer targeted liposomes containing superparamagnetic iron oxide: ferrosomes. In: Proceedings of the 8th Annual Scientific Meeting of the Society of Magnetic Resonance in Medicine, Amsterdam, 1989. p 327.
30. White DL, Tzika AA, Aicher KP, Engelstad BL, Price DC. Plasma clearance of ferrosomes, a long-lived superparamagnetic MRI contrast agent. In: Proceedings of the 9th Annual Scientific Meeting of the Society of Magnetic Resonance in Medicine, New York, 1990. p 51.
31. Bulte JWM, Ma LD, Magin RL, et al. Selective MR imaging of labeled human peripheral blood mononuclear cells by liposome mediated incorporation of dextran-magnetite particles. Magn Reson Med 1993;29:32-37.
32. Bogdanov AA Jr, Martin C, Weissleder R, Brady TJ. Trapping of dextran-coated colloids in liposomes by transient binding to amino-phospholipid: preparation of ferrosomes. Biochim Biophys Acta 1994;1193:212-218.
33. Päuser S, Reszka R, Wagner S, Wolf K-J, Buhr H-J, Berger G. Liposome-encapsulated superparamagnetic iron oxide particles as markers in an MRI-guided search for tumor-specific drug carriers. Anti-Cancer Drug Design 1997;12:125-135.
34. 59Fe containing liposomes as a potential specific contrast for MR imaging and micro-autoradiography. In: Proceedings of the 6th Annual Scientific Meeting of the International Society for Magnetic Resonance in Medicine, Sydney, Australia, 1998. p 1173.
35. 4 nanocolloids. Langmuir 1991;7:647-652.
36. De Cuyper M, Noppe W. Extractability of the phospholipid envelope of magnetoliposomes by organic solvents. J Coll Interface Sci 1996;182:478-482.
37. Bulte JWM, Vymazal J, Brooks RA, Pierpaoli C, Frank JA. Frequency dependence of MR relaxation times. II. Iron oxides. J Magn Reson Imaging 1993;3:641-648.
38. Vymazal J, Bulte JWM, Frank JA, Di Chiro G, Brooks RA. Frequency dependence of MR relaxation times. I. Paramagnetic ions. J Magn Reson Imaging 1993;3:637-640.
39. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:661-674.
40. Pochon S, Hyacinthe R, Terrettaz J, Robert F, Schneider M, Tournier H. Long circulating superparamagnetic particles with high T2 relaxivity. Acta Radiol 1997;412:69-72.
41. Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1994;1195:11-20.
42. Moore SG, Dawson KL. Red and yellow marrow in the femur: age-related changes in appearance at MR imaging. Radiology 1990; 175:219-223.
43. Podda S, Ward M, Himelstein A. et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992;89:9676-80.
44. Sorrentino BP, Brandt SJ, Bodino G, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDRI. Science 1992;257:99-103.
45. Koç OM, Allay JA, Lee K, Davis BM, Reese JS, Gerson SL. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 1996;23:46-65.
46. Hesdorffer C, Ayello J, Ward M, et al. Phase I trial of retroviral-mediated transfer of the human MDRI gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998;16:165-172.